Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Stratagen Quantitative Prostate MRI Platform Pilot Study

NCT: NCT06985238 · ACTIVE_NOT_RECRUITING

NCT IDNCT06985238
StatusACTIVE_NOT_RECRUITING
Start Date2025-09-24
Completion2027-05-30
SponsorStratagen Bio, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to assess the safety and feasibility of the Stratagen Quantitative Prostate MRI Platform when used in addition to the standard scans conducted during the existing prostate MRI sessions. * What severe problems, if any, occur because of the use of the Stratagen Quantitative Prostate MRI Platform? * Can the data collected be used to measure quantitative MRI parameters? Participants will: \- Receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑